Literature DB >> 8339274

Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group.

C D James1, J He, V P Collins, M J Allalunis-Turner, R S Day.   

Abstract

Southern blot analyses of the 9p-localized type I interferon (IFN) genes in DNAs obtained from malignant glioma cell lines and glial tumor tissue have indicated that homozygous deletions of the IFN-alpha and IFN-beta genes often occur during the development of the highly malignant central nervous system neoplasm, glioblastoma. We have applied a set of markers that span the IFN region on 9p to the analysis of DNAs from 30 human glioma cell lines in order to define the region of homozygous deletion associated with this cancer more precisely. Fourteen of the cell lines revealed either complete (12 cases) or partial (2 cases) homozygous deletions of the IFN-alpha gene cluster; no instances of homozygous deletions were observed that did not involve the IFN-alpha region. Genomic DNA identified by the markers nearest to and flanking the IFN-alpha genes were retained in 5 of the cases with homozygous deletions. Consequently, these results limit the extent of homozygous deletions in glioma cell lines to a small region of 9p21-p22 that includes most of the type I IFN locus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339274

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.

Authors:  C Van Lint; C A Amella; S Emiliani; M John; T Jie; E Verdin
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  P16 deletion and mutation analysis in human brain tumors.

Authors:  F G Barker; P Chen; F Furman; K D Aldape; M S Edwards; M A Israel
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Authors:  H M Pomykala; S K Bohlander; P L Broeker; O I Olopade; M O Díaz
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

Review 4.  Progress against cancer.

Authors:  S Broder; J E Karp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Downregulated expression of HSP27 in human low-grade glioma tissues discovered by a quantitative proteomic analysis.

Authors:  Guobo Shen; Shufang Liang; Zhizhong Xu; Liangxue Zhou; Shiyin Xiao; Xiangying Xia; Ronghui Li; Ying Liao; Chao You; Yuquan Wei
Journal:  Proteome Sci       Date:  2010-03-26       Impact factor: 2.480

6.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 7.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

8.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

9.  Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Authors:  M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Authors:  J Mora; M Alaminos; C de Torres; P Illei; J Qin; N-K V Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.